Form 13-F position report

SAREPTA THERAPEUTICS INC COM S

Reported by JPMorgan Chase & Co

SRPT CUSIP 803607100 Manager CIK 0000019617

Reported 3,702,944 shares, up 2,459,497 (197.8%) from the prior quarter.

Reported value 216.8%; share count 197.8% vs. the prior quarter.

Added
% of reported 13F value 0.06% This manager · Q1 2023
Shares 3,702,944 Quarter-end amount reported
Reported value $510,376,000 Fair value at quarter end
Consecutive quarters held 30 Through Q1 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 139958000
2021-12-31 94429000
2022-03-31 85202000
2022-06-30 76741000
2022-09-30 79700000
2022-12-31 161127000
2023-03-31 510376000
2023-06-30 504356754
2023-09-30 558619991
2023-12-31 125605607
2024-03-31 236730917
2024-06-30 291315502
2024-09-30 274618499
2024-12-31 245685241
2025-03-31 143239649
2025-06-30 11152946
2025-09-30 12899376
2025-12-31 16010622
2026-03-31 14401351
2026-06-30 9345699

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for SAREPTA THERAPEUTICS INC COM S held by JPMorgan Chase & Co.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 544,392 -158,799 (-22.6%) < 0.01% $9,345,699 2026-08-12
Q1 2026 Reduced 703,191 -40,797 (-5.5%) < 0.01% $14,401,351 2026-05-13
Q4 2025 Added 743,988 +74,606 (11.1%) < 0.01% $16,010,622 2026-02-11
Q3 2025 Added 669,382 +17,183 (2.6%) < 0.01% $12,899,376 2025-11-07
Q2 2025 Reduced 652,199 -1,592,233 (-70.9%) < 0.01% $11,152,946 2025-08-12
Q1 2025 Added 2,244,432 +223,828 (11.1%) 0.01% $143,239,649 2025-05-12
Q4 2024 Reduced 2,020,604 -178,279 (-8.1%) 0.02% $245,685,241 2025-02-12
Q3 2024 Added 2,198,883 +355,114 (19.3%) 0.02% $274,618,499 2024-11-08
Q2 2024 Added 1,843,769 +15,167 (0.8%) 0.02% $291,315,502 2024-08-12
Q1 2024 Added 1,828,602 +526,045 (40.4%) 0.02% $236,730,917 2024-05-10
Q4 2023 Reduced 1,302,557 -3,305,758 (-71.7%) 0.01% $125,605,607 2024-02-12
Q3 2023 Added 4,608,315 +204,222 (4.6%) 0.06% $558,619,991 2023-11-14
Q2 2023 Added 4,404,093 +701,149 (18.9%) 0.05% $504,356,754 2023-08-11
Q1 2023 Added 3,702,944 +2,459,497 (197.8%) 0.06% $510,376,000 2023-05-11
Q4 2022 Added 1,243,447 +522,434 (72.5%) 0.02% $161,127,000 2023-02-13
Q3 2022 Reduced 721,013 -302,735 (-29.6%) 0.01% $79,700,000 2022-11-14
Q2 2022 Reduced 1,023,748 -66,918 (-6.1%) 0.01% $76,741,000 2022-08-11
Q1 2022 Added 1,090,666 +42,043 (4.0%) 0.01% $85,202,000 2022-05-11
Q4 2021 Reduced 1,048,623 -464,770 (-30.7%) 0.01% $94,429,000 2022-02-10
Q3 2021 Added 1,513,393 +207,051 (15.8%) 0.02% $139,958,000 2021-11-12
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

476 managers reported SAREPTA THERAPEUTICS INC COM S for Q1 2023.

Managers reporting SAREPTA THERAPEUTICS INC COM S in Q1 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 8,112,964 +79,700 0.03% $1,118,209,828 40 qtrs
BlackRock Inc Reduced 5,282,695 -199,471 0.02% $728,113,851 40 qtrs
JANUS HENDERSON GROUP PLC Reduced 4,908,204 -1,119,812 0.45% $676,528,232 20 qtrs
JPMorgan Chase & Co This report Added 3,702,944 +2,459,497 0.06% $510,376,000 30 qtrs
Avoro Capital Advisors LLC Added 3,650,000 +475,000 7.46% $503,079,500 20 qtrs
EcoR1 Capital LLC Unchanged 2,999,453 0 13.31% $413,414,607 5 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 2,933,612 +379,548 0.08% $404,339,742 21 qtrs
FMR LLC Reduced 2,644,656 -71,415 0.03% $364,512,945 40 qtrs
THE BANK OF NEW YORK MELLON CORPORATION Reduced 1,914,718 -79,115 0.06% $263,905,560 40 qtrs
STATE STREET CORPORATION Reduced 1,773,976 -167,768 0.01% $244,506,927 40 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2023
Filed
May 11, 2023
Filing type
13F-HR
Position type
COMMON

Voting authority reported

Sole
3,313,951
Shared
10
None
388,983

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.